申请人:Incyte Corporation
公开号:US10112950B2
公开(公告)日:2018-10-30
The present invention is directed to imidazo[1,2-a]pyrazine derivatives of Formula I, or a pharmaceutically acceptable salt thereof, which are LSD1 inhibitors useful in the treatment of diseases such as cancer.
本发明涉及式 I 的咪唑并[1,2-a]吡嗪衍生物或其药学上可接受的盐,它们是治疗癌症等疾病的 LSD1 抑制剂。